Life sciences and medical device companies are dealing with an unprecedented crisis. The industry is not only managing the impact of Coronavirus (COVID-19), they are also a solution provider. Companies are rapidly adapting products, services, facilities and distribution channels to aid in the pandemic response. Simultaneously, they must maintain shareholder value, navigate highly complex regulatory hurdles and compliance obligations while rethinking strategies for growth in a post-COVID-19 world.

Join a team of seasoned professionals from McDermott Will & Emery and Ernst & Young, LLP for insights and guidance on critical COVID-19-related operational, regulatory and legal developments, including:

• R&D, Clinical Trials and the FDA
• Supply Chain Adaption and Compliance
• The CARES Act and Accessing Government Funds
• Restructuring and Solvency Strategies

For any questions, please contact Laura McAllister at [email protected].